Literature DB >> 11251621

Markers of active airway inflammation and remodelling in chronic obstructive pulmonary disease.

S R Rutgers1, W Timens, H F Kauffman, D S Postma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11251621     DOI： 10.1046/j.1365-2222.2001.01004.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN： 0954-7894            Impact factor:   5.018


× No keyword cloud information.
  7 in total

Review 1.  Pneumocystis: a novel pathogen in chronic obstructive pulmonary disease?

Authors:  Alison Morris; Frank C Sciurba; Karen A Norris
Journal:  COPD       Date:  2008-02       Impact factor: 2.409

2.  Association of current smoking with airway inflammation in chronic obstructive pulmonary disease and asymptomatic smokers.

Authors:  Brigitte W M Willemse; Nick H T ten Hacken; Bea Rutgers; Dirkje S Postma; Wim Timens
Journal:  Respir Res       Date:  2005-04-25

3.  PM2.5 promotes human bronchial smooth muscle cell migration via the sonic hedgehog signaling pathway.

Authors:  Xiuqin Ye; Wei Hong; Binwei Hao; Gongyong Peng; Lingmei Huang; Zhuxiang Zhao; Yumin Zhou; Mengning Zheng; Chenglong Li; Chunxiao Liang; Erkang Yi; Jinding Pu; Bing Li; Pixin Ran
Journal:  Respir Res       Date:  2018-03-02

4.  Sputum analysis in diagnosis and management of obstructive airway diseases.

Authors:  Paige Lacy; Jennifer L Lee; Dilini Vethanayagam
Journal:  Ther Clin Risk Manag       Date:  2005-09       Impact factor: 2.423

Review 5.  Heme oxygenase-1 and carbon monoxide in pulmonary medicine.

Authors:  Dirk-Jan Slebos; Stefan W Ryter; Augustine M K Choi
Journal:  Respir Res       Date:  2003-08-07

6.  Central airways remodeling in COPD patients.

Authors:  Laura Pini; Valentina Pinelli; Denise Modina; Michela Bezzi; Laura Tiberio; Claudio Tantucci
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-09-01

7.  Scutellaria baicalensis Attenuates Airway Remodeling via PI3K/Akt/NF-κB Pathway in Cigarette Smoke Mediated-COPD Rats Model.

Authors:  Fei Xu; Jinpei Lin; Wenqiang Cui; Qing Kong; Qiuping Li; Lulu Li; Ying Wei; Jingcheng Dong
Journal:  Evid Based Complement Alternat Med       Date:  2018-05-13       Impact factor: 2.629
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.